StreetAlpha.app
Home › Stocks › ARCT

Arcturus Therapeutics Holdings Inc. (ARCT)

Healthcare
$7.97
▼ −4.09%
LAST CLOSE · NOV 17

Arcturus Therapeutics develops mRNA medicines for rare diseases and a COVID-19 vaccine, KOSTAIVE, with partner CSL Seqirus. It last closed at $7.97 on Nov 17, down 4.09% on the day. The average 12-month price target from 3 analysts is $19.67 (+146.8% from the last close), with a high of $20.00 and a low of $19.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ARCT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$30.5M
−68.7% vs a year ago
Net income
−$87.2M
−285.9% margin
EPS (diluted)
−$3.10
Free cash flow
−$62.5M
−204.9% margin
Valuation
Market cap
$229.7M
28.8M shares
P/E
–
No P/E while losing money
Price to sales
7.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$184.8M
At Sep 30
Shareholder equity
$168.7M
Shares outstanding
28.8M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $12.4M$12.4MFY2021FY2022: $206.0M$206.0MFY2022FY2023: $166.8M$166.8MFY2023FY2024: $152.3M$152.3MFY2024FY2025: $82.0M$82.0MFY2025

From ARCT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ARCT in the past 90 days
Average 12-month target
$19.67
▲ 146.8% upside

Based on 3 analysts who set a price target on ARCT in the past 90 days. The average target is $19.67, with a high of $20.00 and a low of $19.00, compared with the last close of $7.97.

Low $19.00Avg $19.67High $20.00
Blue marker: last close $7.97
Highest target$20.00
Average target$19.67
Lowest target$19.00
Latest rating changes
Leerink PartnersMaintained
Oct 9Buy$19
CitigroupUpgrade
Sep 24Buy$20
BTIGMaintained
Sep 24Buy$20
Freedom BrokerInitiated
Jul 2Buy$27
DateFirmActionRatingPrice target
Oct 9Leerink PartnersMaintainedBuy$19
Sep 24CitigroupUpgradeBuy$20
Sep 24BTIGMaintainedBuy$20
Jul 2Freedom BrokerInitiatedBuy$27
Loading…

Technical Analysis

ARCT · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 25% below its 20 day and 52% below its 50 day average. It is 14% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $7.67, and the nearest resistance the Pivot at $7.99.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 13.2%/day
Key levels
$17.9652 week high+125.3%
$12.1350 day average+52.2%
$10.53100 day average+32.1%
$9.9520 day average+24.8%
$9.11200 day average+14.3%
$8.29Pivot R1+4.0%
$8.05Swing high (May 29)+1.0%
$7.99Pivot+0.3%
$7.97Last close
$7.67Pivot S1−3.8%
$6.71Swing low (Jun 11)−15.8%
$5.5052 week low−31.0%
Indicators
RSI (14)35.24Weak, oversold below 30Neutral
MACD-1.00Below its signal lineBearish
Stochastic4.5Near the bottom of its rangeOversold
ADX (14)17.5No clear trend
Williams %R-94.1Oversold below −80, overbought above −20Oversold
CCI (20)-158.9Oversold below −100, overbought above 100Oversold
Rate of change−16.5%Change over 10 sessionsBearish
ATR (14)$1.05Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARCT

What happened before

See how ARCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ARCT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ARCT in the last 90 days.

Loading…

See today’s whale options flow across the market →

ARCT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲91 buying vs 63 selling
  • ▲Held by funds +1.5 pts
  • ▲Funds holding +19
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding156137+13.9%
In funds' top 1000–
Held by funds88.3%86.8%+1.5 pts
New / increased33 / 5819 / 55+23.0%
Reduced / sold out46 / 1740 / 8+31.3%
Put/call ratio0.680.12+474.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARCT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARCT is in one of them and how their past ARCT trades turned out.

ARCT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARCT in an article yet. Here's the latest on the wider market.

About Arcturus Therapeutics Holdings

Arcturus Therapeutics is a messenger RNA medicines company based in San Diego, California. It develops treatments for rare genetic diseases, including candidates for ornithine transcarbamylase deficiency and cystic fibrosis. The company also develops vaccines, and its KOSTAIVE COVID-19 vaccine is partnered with CSL Seqirus and sold in Japan through Meiji Seika Pharma. Its proprietary LUNAR delivery system and STARR platform are used to build these medicines and vaccines.

Headquarters
San Diego, CA